|
[1]
|
Hansen, K.R., Resta, R., Webb, C.F., et al. (1995) Isolation and Characterization of the Promoter of the Human 5’-Nucleotidase (CD73)-Encoding Gene. Gene, 167, 307-312. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Spychala, J., Zimmermann, A.G. and Mitchell, B.S. (1999) Tis-sue-Specific Regulation of the Ecto-5’-nucleotidase Promoter: Role of the cAMP Response Element Site in Mediating Repression by the Upstream Regulatory Region. Journal of Biological Chemistry, 274, 22705-22712. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Joolharzadeh, P. and St. Hilaire, C. (2019) CD73 (Cluster of Differentia-tion 73) and the Differences between Mice and Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 39, 339-348. [Google Scholar] [CrossRef]
|
|
[4]
|
Sträter, N. (2006) Ecto-5’-nucleotidase: Structure Function Rela-tionships. Purinergic Signalling, 2, Article No. 343. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Knöfel, T. and Sträter, N.E. (2001) Coli 5’-Nucleotidase Undergoes a Hinge-Bending Domain Rotation Resembling a Ball-and-Socket Motion. Journal of Molecular Biology, 309, 255-266. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Knapp, K., Zebisch, M., Pippel, J., et al. (2012) Crystal Structure of the Human Ecto-5’-nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling. Structure, 20, 2161-2173. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Schrader, J. (2011) NT5E Mutations and Arterial Calcifications. The New England Journal of Medicine, 364, 1578-1579. [Google Scholar] [CrossRef]
|
|
[8]
|
Antonioli, L., Pacher, P., Vizi, E.S., et al. (2013) CD39 and CD73 in Im-munity and Inflammation. Trends in Molecular Medicine, 19, 355-367. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Yegutkin, G.G. (2008) Nucleotide- and Nucleoside-Converting Ec-toenzymes: Important Modulators of Purinergic Signalling Cascade. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1783, 673-694. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Chen, S., Zha, X. and Li, Y. (2015) Advance in Targeted Immuno-therapy for Hematological Malignancies Based on Immunosuppressive Receptors. Journal of Leukemia & Lymphoma, No. 12, 449-452.
|
|
[11]
|
Bours, M.J.L., Swennen, E.L.R., Di Virgilio, F., et al. (2006) Adenosine 5’-Triphosphate and Adenosine as Endogenous Signaling Molecules in Immunity and Inflammation. Pharmacology & Therapeutics, 112, 358-404. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Carman, A.J., Mills, J.H., Krenz, A., et al. (2011) Adenosine Receptor Signaling Modulates Permeability of the Blood-Brain Barrier. Journal of Neuroscience, 31, 13272-13280. [Google Scholar] [CrossRef]
|
|
[13]
|
Klinger, M., Freissmuth, M. and Nanoff, C. (2002) Adenosine Receptors: G Protein-Mediated Signalling and the Role of Accessory Proteins. Cellular Signalling, 14, 99-108. [Google Scholar] [CrossRef]
|
|
[14]
|
Eltzschig, H.K., Sitkovsky, M.V. and Robson, S.C. (2012) Pu-rinergic Signaling during Inflammation. New England Journal of Medicine, 367, 2322-2333. [Google Scholar] [CrossRef]
|
|
[15]
|
Aherne, C.M., Kewley, E.M. and Eltzschig, H.K. (2011) The Resurgence of A2B Adenosine Receptor Signaling. Biochimica et Biophysica Acta (BBA)—Biomembranes, 1808, 1329-1339. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Borea, P.A., Gessi, S., Merighi, S., et al. (2018) Pharmacology of Adenosine Receptors: The State of the Art. Physiological Reviews, 98, 1591-1625. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Massaia, M., Perrin, L., Bianchi, A., et al. (1990) Human T Cell Acti-vation. Synergy between CD73 (Ecto-5’-nucleotidase) and Signals Delivered through CD3 and CD2 Molecules. The Journal of Immunology, 145, 1664-1674.
|
|
[18]
|
Dianzani, U., Redoglia, V., Bragardo, M., et al. (1993) Co-Stimulatory Signal Delivered by CD73 Molecule to Human CD45RAhiCD45ROlo (Naive) CD8+ T Lymphocytes. The Journal of Immunology, 151, 3961-3970.
|
|
[19]
|
Beavis, P.A., Stagg, J., Darcy, P.K., et al. (2012) CD73: A Potent Suppressor of Antitumor Immune Responses. Trends in Immunology, 33, 231-237. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Wu, X.R., He, X.S., Chen, Y.F., et al. (2012) High Expression of CD73 as a Poor Prognostic Biomarker in Human Colorec-tal Cancer. Journal of Surgical Oncology, 106, 130-137. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Allard, B., Turcotte, M. and Stagg, J. (2012) CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth. Journal of Biomedicine and Biotechnology, 2012, Article ID: 485156. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Leth-Larsen, R., Lund, R., Hansen, H.V., et al. (2009) Metastasis-Related Plasma Membrane Proteins of Human Breast Cancer Cells Identified by Comparative Quantitative Mass Spectrometry. Molecular & Cellular Proteomics, 8, 1436-1449. [Google Scholar] [CrossRef]
|
|
[23]
|
Loi, S., Pommey, S., Haibe-Kains, B., et al. (2013) CD73 Promotes Anthracycline Resistance and Poor Prognosis in Triple Negative Breast Cancer. Proceedings of the National Academy of Sciences, 110, 11091-11096. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Serra, S., Horenstein, A.L., Vaisitti, T., et al. (2011) CD73-Generated Extracellular Adenosine in Chronic Lymphocytic Leukemia Creates Local Conditions Counteracting Drug-Induced Cell Death. Blood: The Journal of the American Society of Hematology, 118, 6141-6152. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Eltzschig, H.K., Ibla, J.C., Furuta, G.T., et al. (2003) Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium: Role of Ectonucleo-tidases and Adenosine A2B Receptors. The Journal of Experimental Medicine, 198, 783-796. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Morote-Garcia, J.C., Rosenberger, P., Kuhlicke, J., et al. (2008) HIF-1-Dependent Repression of Adenosine Kinase Attenuates Hypoxia-Induced Vascular Leak. Blood: The Journal of the American Society of Hematology, 111, 5571-5580. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Eltzschig, H.K., Abdulla, P., Hoffman, E., et al. (2005) HIF-1-Dependent Repression of Equilibrative Nucleoside Transporter (ENT) in Hypoxia. The Journal of Experimental Medicine, 202, 1493-1505. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Sceneay, J., Smyth, M.J. and Möller, A. (2013) The Pre-Metastatic Niche: Finding Common Ground. Cancer & Metastasis Reviews, 32, 449-464. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Wang, L., Fan, J., Thompson, L.F., et al. (2011) CD73 Has Distinct Roles in Nonhematopoietic and Hematopoietic Cells to Promote Tumor Growth in Mice. The Journal of Clinical Investi-gation, 121, 2371-2382. [Google Scholar] [CrossRef]
|
|
[30]
|
Wang, L., Zhou, X., Zhou, T., et al. (2008) Ecto-5’-nucleotidase Promotes Inva-sion, Migration and Adhesion of Human Breast Cancer Cells. Journal of Cancer Research and Clinical Oncology, 134, 365-372. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Zhou, P., Zhi, X., Zhou, T., et al. (2007) Overexpression of Ec-to-5’-nucleotidase (CD73) Promotes T-47D Human Breast Cancer Cells Invasion and Adhesion to Extracellular Matrix. Cancer Biology & Therapy, 6, 426-431. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Li, X., Wen, Y., Miao, X., et al. (2014) NT5E and FcGBP as Key Regulators of TGF-1-Induced Epithelial-Mesenchymal Transition (EMT) Are Associated with Tumor Progression and Survival of Patients with Gallbladder Cancer. Cell and Tissue Research, 355, 365-374. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Wang, H., Lee, S., Nigro, C.L., et al. (2012) NT5E (CD73) Is Epige-netically Regulated in Malignant Melanoma and Associated with Metastatic Site Specificity. British Journal of Cancer, 106, 1446-1452. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Lu, X.X., Chen, Y.T., Feng, B., et al. (2013) Expression and Clinical Signifi-cance of CD73 and Hypoxia-Inducible Factor-1α in Gastric Carcinoma. World Journal of Gastroenterology: WJG, 19, 1912-1918. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Yang, Q., Du, J. and Zu, L. (2013) Overexpression of CD73 in Prostate Cancer Is Associated with Lymph Node Metastasis. Pathology & Oncology Research, 19, 811-814. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Liu, N., Fang, X.D. and Vadis, Q. (2012) CD73 as a Novel Prognostic Biomarker for Human Colorectal Cancer. Journal of Surgical Oncology, 7, 918-919. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Wieten, E., Van Der Linden-Schrever, B.E.M., Sonneveld, E., et al. (2011) CD73 (5’-nucleotidase) Expression Has No Prognostic Value in Children with Acute Lymphoblastic Leukemia. Leukemia, 25, 1374-1376. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Quezada, C., Garrido, W., Oyarzún, C., et al. (2013) 5’-Ectonucleotidase Me-diates Multiple-Drug Resistance in Glioblastoma Multiforme Cells. Journal of Cellular Physiology, 228, 602-608. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Turcotte, M., Allard, D., Mittal, D., et al. (2017) CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research, 77, 5652-5663. [Google Scholar] [CrossRef]
|
|
[40]
|
Siu, L.L., Burris, H., et al. (2018) Abstract CT180: Preliminary Phase 1 Profile of BMS-986179, an Anti-CD73 Antibody, in Combination with Nivolumab in Patients with Advanced Solid Tumors. Cancer Research, 78, CT180.
|
|
[41]
|
Overman, M.J., LoRusso, P., Strickler, J.H., et al. (2018) Safety, Ef-ficacy and Pharmacodynamics (PD) of MEDI9447 (Oleclumab) Alone or in Combination with Durvalumab in Advanced Colorectal Cancer (CRC) or Pancreatic Cancer (PANC). Journal of Clinical Oncology, 36, 4123-4123. [Google Scholar] [CrossRef]
|
|
[42]
|
Stewart, S., Buonpane, R., Zhou, J., et al. (2021) Abstract LB174: Discovery and Preclinical Characterization of INCA00186, a Humanized Monoclonal Antibody Antagonist of CD73, as a Cancer Immunotherapy. Cancer Research, 81, LB174. [Google Scholar] [CrossRef]
|